Chief Executive Officer CEO of Vertebrate Antibodies Ltd

"Vertebrate Antibodies Ltd (VAL) is a biotech spinout company from the University of Aberdeen with a focus on the development of antibodies to targets within a wide range of organisms for research and clinical applications. VAL supports the life sciences community by providing and developing a large range of high quality antibodies. We have been working with CRT Reagents to commercialise our antibodies since they were recommended to us in May 2013, and it is now the main distributor for large proportion of our Research reagents.

VAL‘s main strength is its novel and high throughput technology in generating monoclonal antibodies. But, as an early stage company, VAL has a limited customer network, marketing team and distributing companies.Working with CRT has enabled us to focus on our core competencies while drawing on CRT’s extensive network, marketing expertise and distribution team. Our partnership with CRT Reagents has been key factor in our success."

Ayham Alnabulsi
Chief Executive Officer CEO
at Vertebrate Antibodies Ltd

Read our related post on Vertebrate Antibodies here.